A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.
NCT00145171
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
56
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson Disease
Interventions
DRUG:
apomorphine HCl injection
Sponsor
Mylan Bertek Pharmaceuticals